Search

Data management across servers has grown problematic because of technological advancements in data processing and storage capacities. Data that is neither organized nor labelled adds an additional layer of difficulty to the storing and retrieving processes. This data, which is not tagged, requires analytic techniques that are more powerful and time efficient. Clustering has long been regarded as one of the most effective methods for managing large amounts of data; nonetheless, larger volumes can lead to unexpectedly poor accuracy when using conventional clustering methodologies. In this study, we suggest the use of a novel framework for the clustering of large amounts of data. The preprocessing stage is one of the most important parts in the data cleansing process; hence, a global stop-word list is used to filter the contents of the files before sending them on to the cluster distribution stage. A meta-heuristic focused Genetic Algorithm (GA) is utilized to eradicate the redundant information present in the datasets. In addition to the generalized attributable fitness function, an attribute-based innovative fitness function (f) is being developed. To determine how well proposed method performs, it is compared to a variety of alternative clustering approaches. When comparing the distributions of clusters for the purpose of evaluation, the Standard Error (SE), root mean squared error (RMSE), and corrected R squared error are all computed. [ABSTRACT FROM AUTHOR]

Extracorporeal membrane oxygenation (ECMO) was first started for humans in early 1970s by Robert Bartlett. Since its inception, there have been numerous challenges with extracorporeal circulation, such as coagulation and platelet activation, followed by consumption of coagulation factors and platelets, and biocompatibility of tubing, pump, and oxygenator. Unfractionated heparin (heparin hereafter) has historically been the defacto anticoagulant until recently. Also, coagulation monitoring was mainly based on bedside activated clotting time and activated partial thromboplastin time. In the past 50 years, the technology of ECMO has advanced tremendously, and thus, the survival rate has improved significantly. The indication for ECMO has also expanded. Among these are clinical conditions such as postcardiopulmonary bypass, sepsis, ECMO cardiopulmonary resuscitation, and even severe coronavirus disease 2019 (COVID-19). Not surprisingly, the number of ECMO cases has increased according to the Extracorporeal Life Support Organization Registry and prolonged ECMO support has become more prevalent. It is not uncommon for patients with COVID-19 to be on ECMO support for more than 1 year until recovery or lung transplant. With that being said, complications of bleeding, thrombosis, clot formation in the circuit, and intravascular hemolysis still remain and continue to be major challenges. Here, several clinical ECMO experts, including the "Father of ECMO"—Dr. Robert Bartlett, describe the history and advances of ECMO. [ABSTRACT FROM AUTHOR]

Background: Throughout the COVID‐19 pandemic, the mortality of critically ill patients remained high. Our group developed a treatment regimen targeting sepsis and ARDS which we labeled "triple therapy" consisting of (1) corticosteroids, (2) therapeutic plasma exchange (TPE), and (3) timely intubation with lung protective ventilation. Our propensity analysis assesses the impact of triple therapy on survival in COVID‐19 patients with sepsis and ARDS. Methods: Retrospective propensity analysis comparing triple therapy to no triple therapy in adult critically ill COVID‐19 patients admitted to the Intensive Care Unit at Lexington Medical Center from 1 March 2020 through 31 October 2021. Results: Eight hundred and fifty‐one patients were admitted with COVID‐19 and 53 clinical and laboratory variables were analyzed. Multivariable analysis revealed that triple therapy was associated with increased survival (OR: 1.91; P =.008). Two propensity score‐adjusted models demonstrated an increased likelihood of survival in patients receiving triple therapy. Patients with thrombocytopenia were among those most likely to experience increased survival if they received early triple therapy. Decreased survival was observed with endotracheal intubation ≥7 days from hospital admission (P <.001) and there was a trend toward decreased survival if TPE was initiated ≥6 days from hospital admission (P =.091). Conclusion: Our analysis shows that early triple therapy, defined as high‐dose methylprednisolone, TPE, and timely invasive mechanical ventilation within the first 96 hours of admission, may improve survival in critically ill septic patients with ARDS secondary to COVID‐19 infection. Further studies are needed to define specific phenotypes and characteristics that will identify those patients most likely to benefit. [ABSTRACT FROM AUTHOR]

Inter-specific hybridization between the two cultivated species of barnyard millet, Echinochloa frumentacea (Indian barnyard millet) and E. esculenta (Japanese barnyard millet) holds enormous potential for their mutual genetic enhancement. Here, we report the success in obtaining inter-specific hybrid between E. esculenta and E. frumentacea involving cultivars PRJ 1 and ER 72 of the two species, respectively. The hybridity of F1 plants was confirmed through rice SSR (Simple Sequence Repeat) markers. The hybrid plants of the cross PRJ 1 x ER 72 were vigorous, heavily tillered with high culm branching and were free from grain smut disease but failed to set seed due to sterility. Successful hybridization between the two species opens up vast avenues for introgression of desirable traits and exploitation of genetic variability present in the two species for their mutual genetic improvement, besides a wide array of conventional and genomic researches particularly dissection of traits such as yield and disease resistance.